We may earn revenue from the products available on this page and participate in affiliate programs. Learn more › TL;DR: Microsoft Visual Studio Professional 2026 is $49.99 (reg. $499.99), delivering a ...

Microsoft is focusing on long-term stability and more flexible developer tooling with its new “AI-native” Visual Studio 2026 IDE and .NET 10. These new releases are aimed at two main business goals: ...

The threat actor skill floor may soon lower as vibe coded ransomware has seemingly been published as an extension for Microsoft's AI code editor Visual Studio Code (VS Code). John Tuckner, founder of ...

Credit: Image generated by VentureBeat with FLUX-pro-1.1-ultra A quiet revolution is reshaping enterprise data engineering. Python developers are building production data pipelines in minutes using ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Here's what you need to know ...

Design company Figma today announced multiple features, including AI-powered site and web app creation, a way for marketers to create assets in bulk, and a new drawing tool. With this launch, the ...

On Tuesday, Microsoft Corporation (NASDAQ:MSFT) announced a research preview of "Computer Use," a new tool within Copilot Studio that enables AI agents to perform tasks on desktop and web applications ...

Grok, the chatbot from Elon Musk’s AI company, xAI, has gained a canvas-like feature for editing and creating documents and basic apps. Called Grok Studio, the feature was announced on X late Tuesday.

The latest version of OpenAI’s image generation technology has resulted in a flood of users sharing images on social media that have been transformed in the style of Studio Ghibli, the legendary ...

Are you looking for a new place for your student to grow during the 2025-2026 school year? KIPP Texas Public Schools are accepting applications! Kipp Austin Collegiate School Leader, Janice Lopez, ...

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...